Pyruvate Kinase M2 Activators for the Treatment of Cancer
Lead Investigator: Matthew Boxer (NCATS)
Inventors: Douglas Auld (NCATS), Craig Thomas (NCATS), Min Shen (NCATS)
Ref. No.: E-120-2010/0
Abstract: NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.